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Abstract
Background: Venous thromboembolic events (VTE) are common in cancer patients and associated with higher
mortality. In vivo thrombosis and anticoagulation might be involved in tumor growth and progression. We studied
the association of warfarin and other anticoagulant use as antithrombotic medication and prostate cancer (PCa)
death in men with the disease.
Methods: The study included 6,537 men diagnosed with PCa during 1995-2009. Information on anticoagulant use
was obtained from a national reimbursement registry. Cox regression with adjustment for age, PCa risk group,
primary therapy and use of other medication was performed to compare risk of PCa death between warfarin users
with 1) men using other types of anticoagulants and 2) non-users of anticoagulants. Medication use was analyzed
as a time-dependent variable to minimize immortal time bias.
Results: In total, 728 men died from PCa during a median follow-up of 9 years. Compared to anticoagulant non-
users, post-diagnostic use of warfarin was associated with an increased risk of PCa death (overall HR 1.47, 95% CI 1.
13-1.93). However, this was limited to low-dose, low-intensity use. Otherwise, the risk was similar to anticoagulant
non-users. Additionally, we found no risk difference between warfarin and other types of anticoagulants.
Pre-diagnostic use of warfarin was not associated with the risk of PCa death.
Conclusions: We found no reduction in risk of PCa death associated with warfarin use. Conversely, the risk was
increased in short-term use, which is probably explained by a higher risk of thrombotic events prompting warfarin
use in patients with terminal PCa.
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Background
Venous thromboembolism (VTE) has been proposed as
prognostic factor in prostate cancer (PCa). VTE is
common in cancer patients and associated with poor
prognosis, risk of death is 8-fold higher in cancer patient
with VTE [1–3]. This applies to PCa as well [4]. VTE in
PCa patients has been associated with more than 6-fold
mortality in both symptomatic and incidental venous
thromboembolic diseases [5]. Thus, anticoagulant drugs
could have an impact on PCa prognosis by reducing
deaths from VTE. Furthermore, anticoagulants, including
warfarin, have shown promising antitumor properties
in vivo [6–10] mainly in lung and breast cancer.
Previous fairly small studies on anticoagulant use and
PCa survival have reported differing results [11–13]. A
potential explanation could be confounding by indica-
tion; patients with an advanced cancer are at increased
risk for VTE [14], thus more often prescribed anticoagu-
lants compared to people without cancer. We conducted
a retrospective, population-based cohort study to assess
the association of pre- and post-diagnostic use of
warfarin and other anticoagulants with PCa survival in
the Finnish Randomized Study of Screening for Prostate
Cancer (FinRSPC) [15].
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Methods
Study cohort
FinRSPC includes 80,458 men aged 55-67 years at base-
line (i.e. at FinRSPC randomization). After exclusion of
prevalent PCa cases, the men were randomized during
1996-1999 either to PSA screening at four-year intervals
(the screening arm) or to no intervention (the control
arm). All men were followed via Finnish Cancer Registry,
which covers 99% of cancers diagnosed in Finland [16].
This study included 6,537 incident PCa cases diagnosed
during 1996-2013. Clinical information included Gleason
grade and TNM stage (available for 97.3% and 97.7% of
the cases, respectively).
PCa cases were stratified into low/intermediate-risk
and high-risk groups according to the definition of the
European Association of Urology (EAU) [17]. All M1
cases were included in the high-risk group.
Information on deaths was obtained from the Statistics
Finland, which assigns official causes of death based on
mandatory death certificates, covering all deaths in
Finland [18]. The accuracy of information on PCa deaths
was ascertained by the FinRSPC cause of death commit-
tee with an excellent concordance between official
causes of death and the cause of death committee
assignments for PCa (kappa 0.95) [15]. Only deaths with
PCa (ICD-10 code C61) as the primary cause of death
were regarded as PCa deaths.
A sensitivity analysis with PCa as an intermediate
cause of death was also performed.
Information on anticoagulant usage
In order to obtain information on anticoagulant drug
purchases during 1995-2009, the study cohort was
linked to a national medication reimbursement database
maintained by the Finnish Social Insurance Institution
(SII) using the unique personal identification code as the
key. As a part of the national health insurance that
covers all Finnish citizens, SII provides reimbursements
for purchases of physician-prescribed drugs [19].The re-
imbursement is 50-100 % depending on the indication
and severity of the condition. In Finland, anticoagulant
drugs are available only through physicians’ prescrip-
tion, thus all anticoagulant purchases in outpatient set-
ting are registered by the database. Drugs used during
hospital inpatient periods are not registered.
All 13 anticoagulant drugs used in outpatient setting
during the study period were identified based on their
ATC codes (Additional file 1: Table S1). Additionally, we
obtained information on cholesterol-lowering drugs,
antidiabetic and antihypertensive drugs, aspirin and
other NSAIDs and alpha-blockers. We also collected
information on primary therapy of PCa (radical prosta-
tectomy, external beam radiation therapy (EBRT), hor-
monal therapy or active surveillance/watchful waiting).
Other medication served as a proxy for co-morbidities,
as they may influence survival [20–25].
The information from the National Care Register for
Health Care maintained by the National Institute for
Health and Welfare included provided diagnoses of
conditions serving as indications for anticoagulant use:
atrial fibrillation (ICD-10: I48), venous thromboembol-
ism (all recorded I82 diagnoses in the study population),
pulmonary embolism (ICD-10: I26.0, I26.9) and throm-
bocytosis. The register covers all of Finland and registers
all diagnoses made during in- and out-patient hospital
visits during 1996-2014, but does not cover diagnoses
from primary care [26]. Additionally, we stratified the
analysis by Charlson Comorbidity Score [27] calculated on
basis of the registered diagnoses for subgroup analysis.
Statistical analysis
Cox proportional hazards regression was used to calcu-
late hazard ratios (HR) and 95% confidence intervals
(CIs) for PCa death. Follow-up started at PCa diagnosis
and continued until death, emigration from Finland or
January 1st, 2015, whichever was first. Time metric was
years and months since the PCa diagnosis.
We used two different model adjustments. The first
Cox regression model was adjusted for age only and the
second for age, EAU tumor risk group and other
medications. The analysis was performed separately for
pre-diagnostic and post-diagnostic use of warfarin and
additionally for other types of anticoagulants. Separate
comparisons were performed between all anticoagulant
users and non-users to estimate the overall effect of
anticoagulant usage, and between warfarin users and
men using non-warfarin anticoagulants to estimate
specific effects of warfarin with simultaneous control of
confounding by indication.
For each man in the study cohort, the total annual
amount of medication purchases was calculated for each
calendar year, and then separately for pre- and post-
diagnostic use. Standardization of doses between differ-
ent anticoagulants was performed by dividing the annual
total milligram amount with the standard Defined Daily
Dose (DDD) as listed by the WHO [28]. Each year with
registered anticoagulant purchases, regardless of the
amount, was considered a year of usage. The intensity of
the use was calculated by dividing the cumulative annual
doses with the number of years of usage.
Pre-diagnostic medication use was analyzed as a time-
independent variable, and cumulative pre-diagnostic
anticoagulant usage beginning from 1995 was stratified
by tertiles. Post-diagnostic use was analyzed as a time-
dependent variable; the usage status and cumulative use
were updated separately for each year of follow-up,
beginning from the year of diagnosis.
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All men were categorized as non-users until the
potential first anticoagulant purchase. After the first
purchase, the status was changed into a user, which was
maintained for each year with recorded purchases. Men
who discontinued the purchases during the follow-up
were kept as ever-users. In analysis of warfarin users
compared to non-warfarin users, men were categorized
as warfarin users each year with recorded warfarin
purchases, even if they had used other types of anticoag-
ulants. Only for years with recorded anticoagulant
purchases without warfarin use, were they recorded as
non-warfarin users.
Long-term impact of timing of post-diagnostic anti-
coagulant use was evaluated in lag-time analysis, where
anticoagulant exposure was lagged 1 to 3 years forward
from the actual year of usage i.e. its effect was ignored
for that duration from the first exposure.
Competing risks analysis using Fine and Gray
regression method with non-PCa death and major
thromboembolic diseases as the competing cause of
death was performed.
All statistical analyses were carried out using IBM
SPSS Statistics 22.0. All statistical tests are two-sided.
Results
Population characteristics
During the median follow-up of 9 years after PCa diag-
nosis 2,296 men died, of whom 728 from PCa (Table 1).
The median follow-up from the diagnosis to PCa death
was 3.9 years among men with no post-diagnostic anti-
coagulant use, 4.8 years among warfarin users and 5.8
years in users of other anticoagulants. High-grade
cancers were almost equally distributed in these sub-
categories. Distribution of background characteristics
are presented in Table 1.
Risk of PCa death by pre-diagnostic use of warfarin and
other anticoagulants
In general, when compared to anticoagulant non-users,
there was no clear association between pre-diagnostic
use of warfarin and PCa death in either age-adjusted or
multivariable-adjusted analysis (multivariable-adjusted
HR 1.15, 95% CI 0.88-1.49). No statistically significant
risk trends by cumulative amount or duration of use
were observed (Table 2). However, pre-diagnostic use of
warfarin for 5 years or more was associated with a bor-
derline significant risk increase in the multivariable-
adjusted model (HR 1.49, 95% CI 0.97-2.28).
When users of other anticoagulants were used as the
reference group, warfarin use was not associated with
PCa death. No risk trends by cumulative use were obser-
ver either (Table 2).
Risk of PCa death by post-diagnostic anticoagulant use
In the analysis of post-diagnostic use of warfarin, the
overall risk of PCa death was significantly higher
among warfarin users in comparison to anticoagulant
non-users (multivariable-adjusted HR 1.47, 95% CI
1.13-1.93) (Table 3). The risk association was stron-
gest in low-dose usage (<200 DDD) (multivariable-ad-
justed HR 2.50, 95% CI 1.86-3.36). Short-term (1 year
or less)/low-intensity use (<128 DDD/year) of
warfarin was similarly associated with an increased
risk of PCa death. As the cumulative amounts in-
creased and the duration of usage extended to 2 years
or more, the risk increase was attenuated and was no
longer statistically significant.
The risk PCa death was similar for warfarin and other
anticoagulants (multivariable-adjusted HR 1.01, 95% CI
0.71-1.44). In the stratified analysis, short-term use of
warfarin was associated with an increased risk of PCa
death, but again the risk increase was smaller in high-
intensity use (Table 3).
Lag-time analysis
In order to evaluate long-term effects of warfarin use
and minimize bias due to thrombotic events triggering
the prescription, we performed an analysis lagging
warfarin use by one, two and three years, i.e. relating it
to events at least 1-3 years later than the exposure to
allow for latency. The risk increase compared to anti-
coagulant non-users was decreased already in the ana-
lysis lagged by one year, but remained non-significantly
elevated (Table 3). The risk increase noted in low-dose
usage was found in the 1-year lagged analysis, but after
2-year lag-time it was only borderline significant (two-
year lag-time for ≤200 DDD HR 1.34, 95% CI 0.99-1.83).
In general, extending the lag-time to two or three years
did not substantially alter the results compared to one-
year lag-time analysis.
Lag-time analysis of warfarin use relative to usage of
other anticoagulant drugs was not substantially altered
compared with the non-lagged results. No risk increase
among short-term users or decreased risk among high-
intensity users was found in the lagged analysis (Table 3).
Subgroup analyses
No clear risk modification by any background variable
was present between pre-diagnostic warfarin use and
risk PCa death (Fig. 1). The same applied also to
post-diagnostic use and risk of PCa death (Fig. 2).
Effect modification was not found when comparing
warfarin usage to other types of anticoagulants in
pre- and post-diagnostic setting (Additional file 2:
Figure S1 and Additional file 3: Figure S2)
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Sensitivity analysis
As part of sensitivity analyses, users of any anticoagu-
lants including warfarin were compared to non-users.
There was a borderline significant risk increase among
pre-diagnostic users of anticoagulants (multivariable-ad-
justed HR 1.19, 95% CI 0.96-1.48) (Additional file 4:
Table S2).
In analysis of post-diagnostic use, the risk was increased
(HR 1.58, 95% CI 1.27-1.97), but no apparent risk trends
by cumulative amount or duration were observed. In the
lag-time analyses, no statistically significant risk increase
was present (Additional file 4: Table S3).
No clear effect modification was observed for pre- nor
post-diagnostic use of all anticoagulants (Additional file 5:
Figure S3 and Additional file 6: Figure S4).
Competing risk analysis
In a Fine-Gray regression analysis with non-PCa deaths
as competing cause of death, no risk difference was
observed between users of warfarin and other anticoagu-
lants (HR 0.95, 95% CI 0.74-1.24). The findings were
similar when deaths caused by pulmonary embolism or
stroke were analyzed as the competing causes of death
(HR 0.95, 95% CI 0.73-1.23).
Discussion
Short-term and low-dose warfarin use after the diagnosis
was associated with increased risk of PCa death compared
to anticoagulant non-users. However, in analyses allowing
for lag-time, the risk was attenuated after one year and
disappeared in 2-year or 3-year lag-time analysis. This
suggests that the risk increase occurs only for a short time
period after starting drug use. We found no statistically
significant risk difference between users of warfarin and
other types of anticoagulants. Additionally, we found no
association between pre-diagnostic use of warfarin and
PCa survival. Although the indication for anticoagulant
treatment did not modify the risk association, it is likely
that the short-term increased risk is explained by
thrombotic events as indications for anticoagulation. In
epidemiological literature this phenomenon where
pharmaceutical drug is prescribed for early manifestation
of yet un-diagnosed disease is referred to as ‘protopathic
bias’ [29].
Previous studies on warfarin and PCa mortality are
sparse. To date, three published studies have assessed
the association between PCa survival and use of vitamin
K antagonists [11–13]. Tagalakis et al. found an
increased risk of PCa death associated with one-year or
ever-use of warfarin in after PCa diagnosis [11]. Our
study is consistent with an increased risk associated with
short-term use. In contrast to Tagalakis et al., we were
able to evaluate cumulative amounts and intensity of use
and found that high-dose or long-term use are not
associated with risk increase.
In a cohort study including 12,186 men with PCa, but
no information on stage no evidence was found for an
association between PCa death and pre-diagnostic use of
warfarin during a mean follow-up of 3.7 years [12]. In a
sensitivity analysis post-diagnostic use was associated
with an increased risk of PCa death. Evaluation of cumu-
lative amounts, duration nor intensity of use for post-
Table 2 Pre-diagnostic use of warfarin compared to anticoagulant non-users and warfarin usage in comparison with other
anticoagulant drugs stratified by Defined Daily Doses (DDD), duration and intensity of usage
n of deaths Age-adjusted Multivariable-adjusted
Warfarin compared to non-users
None 624 Ref Ref
Any 65 1.11 (0.85-1.44) 1.15 (0.88-1.49)
Amount of warfarin use
≤200 DDD 24 0.98 (0.65-1.48) 0.97 (0.64-1.47)
201-796 DDD 18 1.09 (0.68-1.74) 1.19 (0.74-1.91)
>796 DDD 23 1.31 (0.86-1.99) 1.37 (0.90-2.09)
Duration of warfarin use
≤1 year 20 0.91 (0.53-1.56) 0.72 (0.42-1.24)
2-4 years 22 0.96 (0.57-1.61) 0.87 (0.52-1.47)
5 or more years 23 1.33 (0.80-2.23) 1.16 (0.69-1.94)
Intensity of warfarin use
≤114 DDD/year 21 0.95 (0.56-1.62) 0.79 (0.47-1.35)
115-200 DDD/year 24 1.09 (0.65-1.81) 0.94 (0.57-1.57)
>200 DDD/year 20 1.10 (0.64-1.89) 0.96 (0.56-1.65)
Age-adjusted and multivariable-adjusted hazard ratios (95% CI) related to all PCa deaths
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diagnostic use was not possible. Concordantly, we ob-
served no risk increase for pre-diagnostic warfarin use.
Compared to the previous study, we had higher of PCa
deaths and were able to evaluate cumulative amount of
post-diagnostic use. We found a risk increase only for
some subgroups.
A third study of Park et al. [13] was limited to 247 pa-
tients with metastatic PCa receiving docetaxel chemo-
therapy, and included only 17 LMWH users and 12
warfarin users. LMWH was associated with an improved
survival, whereas warfarin was not. In our larger and
more comprehensive study, we found no evidence for
improved survival among men using other types of
anticoagulants.
In vitro studies have suggested that the coagulation
cascade and thrombocytes might be involved in tumor
growth and progression, and that anticoagulant drugs
could in theory improve prognosis [6–10]. However,
in epidemiologic studies, confounding by indication
dilutes this potential effect, as advanced cancer is
associated with an increased risk of thrombosis and
consequently with likelihood of initiating anticoagu-
lant treatment. We controlled for such bias by com-
paring users of different types of anticoagulants and
performing a competing risk analysis. We found no
significant risk difference, which does not support the
putative beneficial effect of warfarin or any other
anticoagulants.
Table 3 Post-diagnostic use of warfarin compared to anticoagulant non-users and seperately to users of other types of anticoagu-
lants stratified by Defined Daily Doses (DDD), duration and intensity of usage
n of deaths Age-adjusted Multivariable-adjusted 1-year lag-time 2-year lag-time 3-year lag-time
Warfarin compared to non-users
None 509 Ref Ref Ref Ref Ref
Any 121 1.46 (1.12-1.90) 1.47 (1.13-1.93) 1.12 (0.85-1.48) 1.12 (0.85-1.48) 1.08 (0.83-1.41)
Amount of warfarin use
≤200 DDD 63 2.47 (1.84-3.31) 2.50 (1.86-3.36) 1.45 (1.04-2.02) 1.34 (0.99-1.83) 1.26 (0.94-1.70)
200-667 DDD 32 0.87 (0.53-1.42) 0.88 (0.54-1.46) 0.85 (0.52-1.41) 0.76 (0.44-1.32) 0.76 (0.43-1.36)
>667 DDD 26 0.97 (0.56-1.68) 1.02 (0.59-1.78) 1.05 (0.60-1.83) 1.15 (0.67-1.97) 1.04 (0.58-1.85)
Duration of warfarin use
≤1 year 56 2.03 (1.47-2.81) 2.04 (1.47-2.83) 1.26 (0.89-1.78) 1.25 (0.91-1.71) 1.15 (0.85-1.57)
2-4 years 44 1.28 (0.88-1.87) 1.30 (0.89-1.90) 1.11 (0.73-1.69) 0.87 (0.53-1.42) 0.93 (0.56-1.54)
5 or more years 21 0.95 (0.49-1.85) 1.05 (0.54-2.04) 1.06 (0.56-1.99) 1.37 (0.76-2.47) 1.22 (0.66-2.26)
Intensity of warfarin use
≤128 DDD/year 45 1.92 (1.34-2.74) 1.91 (1.34-2.74) 1.31 (0.91-1.88) 1.35 (0.98-1.86) 1.21 (0.89-1.66)
128-200 DDD/year 51 1.74 (1.24-2.45) 1.77 (1.25-2.50) 1.13 (0.74-1.74) 0.93 (0.57-1.51) 0.94 (0.57-1.56)
>200 DDD/year 25 0.73 (0.40-1.33) 0.78 (0.43-1.43) 0.99 (0.58-1.69) 0.97 (0.56-1.69) 0.99 (0.56-1.77)
Warfarin compared to other anticoagulant drugs
Non-warfarin anticoagulant users 98 Ref Ref Ref Ref Ref
Warfarin users 121 1.13 (0.79-1.61) 1.01 (0.71-1.44) 0.93 (0.64-1.35) 1.02 (0.70-1.48) 0.93 (0.65-1.33)
Amount of warfarin use
≤200 DDD 63 1.85 (1.25-2.74) 1.63 (1.10-2.42) 1.15 (0.75-1.77) 1.19 (0.78-1.80) 1.06 (0.71-1.58)
200-667 DDD 32 0.65 (0.37-1.14) 0.58 (0.33-1.01) 0.68 (0.38-1.20) 0.67 (0.36-1.25) 0.64 (0.34-1.21)
>667 DDD 26 0.72 (0.39-1.33) 0.67 (0.36-1.23) 0.83 (0.45-1.55) 1.02 (0.56-1.87) 0.87 (0.46-1.64)
Duration of warfarin use
≤1 year 56 1.52 (1.00-2.31) 1.33 (0.88-2.02) 1.00 (0.64-1.55) 1.11 (0.73-1.68) 0.97 (0.65-1.45)
2-4 years 44 0.96 (0.61-1.52) 0.85 (0.54-1.34) 0.88 (0.53-1.46) 0.77 (0.44-1.35) 0.78 (0.44-1.38)
5 or more years 21 0.71 (0.35-1.46) 0.69 (0.34-1.40) 0.84 (0.42-1.67) 1.22 (0.64-2.33) 1.02 (0.53-2.00)
Intensity of warfarin use
≤128 DDD/year 45 1.44 (0.93-2.24) 1.25 (0.80-1.95) 1.04 (0.66-1.64) 1.20 (0.78-1.83) 1.02 (0.68-1.53)
128-200 DDD/year 51 1.31 (0.85-2.01) 1.16 (0.75-1.78) 0.90 (0.54-1.49) 0.82 (0.47-1.44) 0.79 (0.45-1.40)
>200 DDD/year 25 0.55 (0.29-1.05) 0.51 (0.27-0.98) 0.79 (0.43-1.44) 0.86 (0.46-1.60) 0.83 (0.44-1.57)
Age-adjusted, multivariable-adjusted and lag-time hazard ratios (95% CI) related to all PCa deaths. Statistically significant results are bolded
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The main strengths of this study are the large
population-based cohort as well as comprehensive
and our ability to use detailed, nationally comprehen-
sive register-based information on anticoagulant use
unaffected by recall bias. Being able to study large
populations through national registries allows us to
estimate even relatively uncommonly used drugs such
as anticoagulants as cancer risk factor. Our study in-
cluded substantially more warfarin users than in pre-
vious studies. We were able to analyze post-diagnostic
use of warfarin more comprehensively than before.
We also performed lag-time analyses to estimate the
risk associations allowing for latency and removing
effects limited to the immediate period following first
subscription. Furthermore, we had longer follow-up
than in previous studies.
Our study also has some limitations. We were not able
to adjust our analysis for smoking, life-style factors or
BMI which may be associated with risk of PCa death
[30–33]. Nevertheless, we were able to adjust for Charl-
son Comorbidity Index and this enabled adjustment for
co-existing morbidities. Furthermore, our study was not
randomized, and is thus prone to residual confounding.
Conclusion
In a population-based setting, warfarin or other types of
anticoagulants are not associated with improved PCa
prognosis. Conversely, in short-term use risk of PCa
death was increased, which is most likely due to throm-
bosis caused by an advanced cancer, as the risk increase
was not observed in long term.
Fig. 1 Pre-diagnostic subgroup analysis of warfarin usage compared to anticoagulant non-users
Fig. 2 Post-diagnostic subgroup analysis of warfarin usage compared to anticoagulant non-users
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